Asepsis announces the USPTO grant of US Patent 9,302,050 for its combinatorial, Calibrated Drug Delivery™ (CDD) platform

Asepsis announces the USPTO grant of U.S. Patent 9,302,050 for its combinatorial, Calibrated Drug Delivery (CDD) platform. The 050 patent continuation further enhances the reconstitution aspects of the CDD injection kit. The completed platform provides the ability for a medicinal injection to be reconstituted and administered via multiple prescribed dosage techniques or patient specific characteristics, without any calculation procedures.

Previous ArticleNext Article